Actively Recruiting
Phase 2b Randomized Study Evaluating AC-101 Tablets for Moderately to Severely Active Ulcerative Colitis
Led by Accro Bioscience (Suzhou) Limited · Updated on 2026-10-28
153
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 2b clinical trial to study AC-101 tablets in adults with moderately to severely active ulcerative colitis UC. The study aims to evaluate the effectiveness, safety, and how the body processes AC-101 compared with a placebo. Participants include those who have not responded well, lost response, or cannot tolerate previous advanced or conventional treatments for UC. Participants will be randomly assigned to one of three groups one receiving a low dose of AC-101 tablets twice daily, another receiving a high dose of AC-101 tablets twice daily, or a placebo group receiving oral placebo tablets twice daily. The study includes a screening period of up to 4 weeks, followed by a 12-week induction treatment phase, then a 40-week extension period for continued treatment, and finally a 4-week safety follow-up after treatment ends. During the study, participants will attend regular visits for assessments of their condition and response to treatment. Researchers will monitor clinical remission at Week 12 as the primary outcome, along with other measures such as clinical response, symptom remission, and any adverse events up to 56 weeks. The total study duration includes screening, treatment, extension, and safety follow-up, lasting over a year for each participant.
CONDITIONS
Brief Title
A Study of AC-101 Tablets in Patients With Ulcerative Colitis
Research Team
Y
Yin Lin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here